Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; email:
Center for Personalized Diagnostics and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Annu Rev Pathol. 2018 Jan 24;13:193-217. doi: 10.1146/annurev-pathol-020117-043803. Epub 2017 Nov 15.
Lymphomas represent clonal proliferations of lymphocytes that are broadly classified based upon their maturity (peripheral or mature versus precursor) and lineage (B cell, T cell, and natural killer cell). Insights into the pathogenetic mechanisms involved in lymphoma impact the classification of lymphoma and have significant implications for the diagnosis and clinical management of patients. Serial scientific and technologic advances over the last 30 years in immunology, cytogenetics, molecular biology, gene expression profiling, mass spectrometry-based proteomics, and, more recently, next-generation sequencing have contributed to greatly enhance our understanding of the pathogenetic mechanisms in lymphoma. Novel and emerging concepts that challenge our previously accepted paradigms about lymphoma biology and how these impact diagnosis, molecular testing, disease monitoring, drug development, and personalized and precision medicine for lymphoma are discussed.
淋巴瘤是淋巴细胞的克隆性增殖，根据其成熟度（外周或成熟与前体）和谱系（B 细胞、T 细胞和自然杀伤细胞）进行广泛分类。对淋巴瘤发病机制中涉及的机制的深入了解影响了淋巴瘤的分类，并对患者的诊断和临床管理具有重要意义。过去 30 年来，免疫学、细胞遗传学、分子生物学、基因表达谱分析、基于质谱的蛋白质组学以及最近的下一代测序技术在科学和技术方面的连续进步，极大地提高了我们对淋巴瘤发病机制的理解。讨论了挑战我们以前关于淋巴瘤生物学的接受范式的新出现的概念，以及这些概念如何影响淋巴瘤的诊断、分子检测、疾病监测、药物开发以及个性化和精准医学。
